Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 3Withdrawn 2Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2

Interventions

Specimen Handling 12Magnetic Resonance Spectroscopy 11Cyclophosphamide 10Biological Therapy 9Drug Therapy 8Dexamethasone 7Biopsy 7antineoplaston A10 6Nivolumab 6Complementary Therapies 6fludarabine 5antineoplaston AS 2-1 5aldesleukin 5Ipilimumab 5Etoposide 5Doxorubicin 5Cisplatin 5atezolizumab 4Vincristine 4Surgical Procedures, Operative 4Rituximab 4Paclitaxel 4Chemotherapy, Adjuvant 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4venetoclax 3olaparib 3dexamethasone acetate 3dexamethasone 21-phosphate 3copanlisib 3auricularum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × NIH × ixazomib × Clear all
NCT01660997 2019-12-16

MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

NCT03856112 2019-03-26

Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡